Education Sessions
Advances in Vaccine Discovery and Manufacturing (205)
| 29 October 08.15-11.15 | Track: Innovation |
ISPE CEUs: 0.2
(PDF Current as of 29 August 2008)
With all the advances in therapeutics, vaccines continue to represent the single most cost-effective medically delivered strategy for confronting the challenges involved in prevention of viral and bacterial diseases. The advancements in vaccine technology development are further hampered by the unique economic, legal, and regulatory issues faced by vaccines.
The desire to be able to create a shield against current and potential threats against the likes of HIV, potential flu pandemic and agents of bio-terrorism continues to fuel vaccine development in spite of all the challenges. As a matter of fact, there has been a tremendous resurgence in vaccine development activity after several decades of relative inactivity. This session intends to bring case studies of real projects to exemplify the current state of vaccine development.
How You Will Benefit
At the end of this session, participants will be able to:
- Identify advances in vaccine manufacturing technology
- Describe scientific challenges still facing vaccine manufacturing development
- Understand the global manufacturing capacity challenges offered by a pandemic outbreak
Who Should Attend
Professionals working in vaccine development and processing
ISPE Communities of Practice (COPs)
Biotechnology (Biotech), Containment, Disposables, Process/Product Development (PPD), Project Management (PM), and Sterile Products Processing (SPP)
Session Leader
- Parrish Galliher, Chief Technology Officer, Xcellerex, Inc., USA
Session Speakers
- Jim Robinson, President, Tech & Qual Ops, Novavax, Inc., USA
- Jane Schneider, R&D Leader, Dowpharma, USA
- Vidadi Yusibov, Executive Director, Fraunhofer Ctr for Molecular Biotech, USA